

UK Biocentre acquired by Azenta to expand biorepository capabilities

Milton Keynes UK – March 4, 2026 – UK Biocentre Limited, a leading provider of sample management, sample storage and high-throughput sample processing services in the United Kingdom, has been acquired by Azenta UK Ltd, a wholly owned subsidiary of Azenta, Inc. (Nasdaq: AZTA).

New ownership and subsequent investment in UK Biocentre will keep the organisation at the forefront of the biobank market, setting international standards for sample quality, governance, accessibility and research.

For Azenta, the acquisition will expand its presence in Europe. It will establish the UK Biocentre as a European-wide operational hub to support pharmaceutical, biotechnology, academic, and public health customers across the region. This major hub will add to its already established biorepository in Griesheim, Germany with current and new customers benefiting from expanded sample storage automated capabilities, reliable and fully integrated sample management and processing services, and a broader European footprint to support the region.

UK Biocentre will continue to operate under its existing name.

Founded in 2014, UK Biocentre supports large scale biomedical, pharmaceutical, and clinical studies, enabling life changing research across academic, pharmaceutical, and biotechnology communities. Its high-quality, automated solutions have made it a trusted partner supporting critical scientific discoveries and population scale programmes.

“Today marks a pivotal moment for UK Biocentre”, said Dr Tony Cox OBE, Chief Executive Officer of UK Biocentre. “Joining Azenta brings together two life science organisations united by a shared commitment to scientific excellence, innovation, and world-class sample management.

“Azenta’s global leadership in sample management, biorepository solutions and genomic services gives us the platform to accelerate our growth, strengthen our infrastructure, and future-proof our capabilities at scale. Together, we will expand our reach across Europe and enhance the services we provide to research, industry and academic science. Our mission remains unchanged: to enable and advance life-changing research. With Azenta’s expertise and

global resources behind us, we are entering an exciting new chapter - delivering even greater impact, resilience and value for our customers and partners.”

John Marotta, President and Chief Executive Officer at Azenta adds, “The acquisition of UK Biocentre is a strategic step in positioning Azenta at the centre of the most critical workflows in the life sciences ecosystem.

“This transaction strengthens our end-to-end sample management solutions platform with deep operational expertise, and enhances our ability to deliver highly scalable, next-generation biorepository capabilities, including the deployment of our 16-million-sample BioArc Ultra, which will further expand our automated, high-throughput capacity later this year. It broadens our global footprint, fully aligns with our disciplined capital allocation strategy, and reinforces our leading positioning across the industry.”

In connection with the transaction, Deloitte acted as financial advisors to the sellers of UK Biocentre, and Osborne Clarke LLP acted as legal advisors to the sellers of UK Biocentre.

ENDS

About UK Biocentre:

UK Biocentre (UKBC) is a leading provider of sample management, sample storage and high-throughput sample processing. UKBC supports and facilitates large-scale studies, enabling life-changing research in the academic, pharmaceutical and biotech communities. UKBC provides end-to-end solutions, from sample collection through to processing, analysis and long-term sample cold storage. <https://www.ukbiocentre.com/>

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling life science organizations around the world to bring impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research and advanced cell therapies for the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. Our global team delivers and supports these products and

services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, and Barkey.

Azenta is headquartered in Burlington, MA, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

MEDIA CONTACT for UK Biocentre

Helen Embleton

helen@ambitiouspr.co.uk

INVESTOR CONTACT for Azenta Life Sciences:

Yvonne Perron

Vice President, Financial Planning & Analysis and Investor Relations

ir@azenta.com

Maria Isabel Cuartas

Manager Investor Relations

ir@azenta.com